Intrexon Corp. and Amneal Pharmaceuticals have formed a second exclusive Channel Collaboration for a target API using Intrexon’s microbial-based expression system with the goal of developing a consistent, scalable, and cost-effective process for the targeted complex API.   This is Amneal and Intrexon’s third partnered program this year involving the microbial technology platform to produce APIs more efficiently. By utilizing pathway development as well as strain and fermentation opti...